---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007709"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-10-08T10:00:40+00:00"
generated_at: "2026-10-12T15:41:44.966101+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Valion Bio signs $50,000 Third Side Letter with 3i for Series B preferred shares and warrants

## Summary
- Valion Bio and 3i, LP entered a Third Side Letter on Oct. 7, 2026, for a $50,000 closing under the Series B Preferred Purchase Agreement.
- 3i agreed to purchase 50 Series B Preferred Shares and Series B Warrants for 1,539 common shares at an initial exercise price of $2.5520 per share.
- The shares and warrants were issued under Section 4(a)(2)/Rule 506(b); Item 3.02 reports the unregistered sales of equity securities.
- The Third Side Letter is Exhibit 10.1; closing conditions include Series B conditions, deliverables, price-adjustment notice, and Nasdaq listing compliance.
- 3i previously purchased 13,637 Series C Preferred Shares for $13,637,000 and holds a $16,253,147.10 note plus Note Warrant for 182,129 shares.

## SEC filing metadata
- accession: 0001683168-26-007709
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-10-08T10:00:40+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826007709/0001683168-26-007709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826007709/valion_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007709
- JSON: https://secwatch.observer/filing/0001683168-26-007709.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007709.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.